INVESTORS
We operate with trust and do the right thing
News
-
AUG 20 2024NewsLazertinib With Amivantamab Approved by FDA for Use in NSCLC
-
DEC 22 2023NewsFDA Considers First-Line Amivantamab Plus Lazertinib in EGFR+ NSCLC
-
JUN 30 2023NewsYuhan's Leclaza indication expanded as 1st-line NSCLC treatment
-
DEC 1 2022NewsYuhan’s Leclaza records 20.6-month mPFS as 1st-line NSCLC therapy
-
JUL 26 2022NewsJanssen Announces New Data Supporting Safety and Efficacy of RYBREVANT® and Lazertinib Combination
-
JUN 8 2021NewsHomegrown anticancer drug lazertinib shows expandabilityA follow-up analysis of using Leclaza (ingredient: lazertinib) in combination with Rybrevant (amivantamab) showed that undiscovered biomarkers other than EGFR and MET expression could broaden the group of patients with potential responses
-
MAY 21 2021NewsJohnson & Johnson snares FDA nod for first exon 20-targeted drug in EGFR lung cancerThe regulator on Friday approved Rybrevant for NSCLC patients whose tumors bear exon 20 mutations and have progressed on or after platinum-based chemotherapy...To further secure success, the company is testing the drug alongside lazertinib...
-
FEB 5 2021NewsLeclaza could change Tagrisso-led lung cancer drug marketLeclaza (ingredient: lazertinib), Korea's 31st novel drug that treats lung cancer, has reached the commercialization stage, raising expectations for a new treatment option
-
SEP 28 2020NewsNew combo therapy will make up for unmet needs of Tagrisso in NSCLC patients...the median progression-free survival (PFS) of the third- generation TKI osimertinib was only about 18 months, and it was shorter in Asians. There are unmet needs in this area, and the combination of lazertinib and amivantamab will improve PFS with good tolerability